High1/3 relationships sourcedProfile verified Aug 14, 2026
OverviewIndicatorsMore SignalsSourcesM&A fitRelationship mapStoryMilestones

30-Second Executive Brief

Executive Assessment

Amgen functions as an established institution within Healthcare & Life Sciences, backed by 47% sourcing coverage, with accelerating strategic relevance.

  • Maintains 3 mapped relationships across the graph
  • 47% sourcing coverage across sourced relationships
  • Tracked as established institution within the Healthcare & Life Sciences category

Executive Snapshot

Strategic Role
Established Institution
Sourcing Coverage
47%
View Methodology →

Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.

Ecosystem Influence
High
Strategic Momentum
Accelerating

Coverage

Mapped Relationships
3
Technology Domains
5

Strategic Implications

  • Central node connecting multiple strategic ecosystems
  • Directly influences technology and capital flows
  • Material relevance to downstream dependency mapping

Top Opportunities

MariTide's Phase III readouts across obesity, cardiovascular disease, heart failure, and sleep apnea through 2026-2027 are the key catalysts for Amgen's obesity-market entry.

Top Risks

Amgen's obesity ambitions now rest entirely on a single asset (MariTide) after discontinuing AMG 513, concentrating pipeline risk.MariTide faces well-established, commercially entrenched competitors in Eli Lilly and Novo Nordisk with multi-year head starts.

Critical Dependencies

Continue to Dependency Graph ↓

A biotechnology company betting its obesity ambitions on MariTide (maridebart cafraglutide), now its sole weight-loss asset after discontinuing early-stage candidate AMG 513 in 2026. MariTide is in Phase III trials across obesity, cardiovascular disease, heart failure, and sleep apnea, with Amgen positioning it as a potential 'best monthly' obesity drug that could allow patients to switch from weekly GLP-1 injections to less-frequent dosing; Amgen raised its 2026 outlook after a Q2 earnings beat, calling 2026 a 'springboard year' as newer products offset pressure on its denosumab franchise.

⚡

Leading Indicators

Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.

Steadyinsider filing activity unchanged since last check
⚡

Additional Intelligence Signals

Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.

Earnings-call mentions

Mentioned by Sarepta Therapeutics

“Dr. Severino brings more than 25 years of biopharmaceutical leadership experience, including senior executive roles at AbbVie, Amgen and Merck”

SEC 8-K exhibit (0001193125-26-335056) · Aug 5, 2026

Mentioned by Generate Biomedicines

“This revenue reflects developments in the ongoing Amgen and Novartis research programs.”

SEC 8-K exhibit (0001193125-26-336462) · Aug 6, 2026

Federal contract disclosures

Department of Health and Human Services — $839,875,190: TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MAJOR CONCERN.

USAspending.gov · Sep 30, 2022

Department of Health and Human Services — $26,408,674: THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF ROMIPLOSTIM FOR TREATMENT OF HEMATOPOIETIC SUBSYNDROME-ACUTE RADIATION SYNDROME (HS-ARS) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT) AND A DRUG DELIVERY DEVICE FEASIBILITY PROJECT WITH AN OPTION TO

USAspending.gov · Sep 26, 2019

Department of Health and Human Services — $7,290,924: NPLATE ADMINISTRATION KIT DEVELOPMENT FOR THE TREATMENT OF APPROVED INDICATIONS, INCLUDING ACUTE RADIATION SYNDROME (ARS)

USAspending.gov · Aug 28, 2023

⚡

Sources

Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.

Evidence

2 sources

Latest Activity

Insider Filing Activity

7Form 4 filings, trailing 90 days0 since last week's snapshot

Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026

Correlated Activity

Both Amgen and Eli Lilly — which it depends on — are showing accelerating Activity at the same time (2 recorded changes for Eli Lilly in the last 90 days).

Timing correlation only — not evidence of a causal link

Both Amgen and CSL Limited — which depends on it — are showing accelerating Activity at the same time (1 recorded change for CSL Limited in the last 90 days).

Timing correlation only — not evidence of a causal link

Both Amgen and Gilead Sciences — which depends on it — are showing accelerating Activity at the same time (1 recorded change for Gilead Sciences in the last 90 days).

Timing correlation only — not evidence of a causal link

⚡

Acquisition & Investment Fit

AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.

⚡

Relationship Map

The relationships surrounding Amgen — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.

2 levels3 levels 🔒5 levels 🔒

Connection type

Sign in free to click a node and explore →

Click any node to make it the new center. Scroll to zoom, drag to pan.

⚡

The Story So Far (last 6 months)

Aug 2026: Q2 2026 earnings beat, raises full-year outlook→Aug 2026: Amgen Q2 deep dive: broad portfolio powers guidance upgrade→Aug 2026: Amgen's obesity strategy now carries all-or-nothing concentration risk after narrowing to… (unconfirmed)

Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.

Market Intelligence

Unverified

Credibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.

Amgen's obesity strategy now carries all-or-nothing concentration risk after narrowing to one asset

32% confidence

Amgen discontinued its early-stage obesity candidate AMG 513 in early 2026, leaving MariTide as its sole weight-loss pipeline asset positioned around a monthly-dosing differentiation versus weekly GLP-1 incumbents.

This is InsightNodes' own interpretive read: narrowing to a single obesity asset is a high-conviction bet that MariTide's monthly-dosing advantage will be commercially meaningful enough to overcome Eli Lilly's and Novo Nordisk's multi-year head start, but it also means Amgen no longer has a fallback candidate if MariTide's Phase III results disappoint in any of its four target indications (obesity, cardiovascular disease, heart failure, sleep apnea) -- a materially higher-risk structure than Pfizer's or Boehringer's still-diversified multi-candidate obesity pipelines.

InsightNodes analysis of Amgen obesity pipeline · Aug 14, 2026

Eli LillyNovo Nordisk
⚡

Amgen's Timeline

A sourced, dated history of Amgen's key moments — founding to present.

  1. Jan 2026 · Discontinues AMG 513, MariTide becomes sole obesity asset

    Amgen discontinued early-stage obesity candidate AMG 513, leaving MariTide as its sole weight-loss pipeline asset and sharpening its focus on extended-dosing differentiation.

  2. Aug 2026 · Q2 2026 earnings beat, raises full-year outlook

    Amgen reported a Q2 2026 earnings beat and raised its full-year outlook, citing broad portfolio strength and continued MariTide Phase III progress.